Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis
Hans‐Peter Hartung(The University of Sydney), Joep Killestein(Amsterdam UMC Location Vrije Universiteit Amsterdam), William M. Carroll(Centre Hospitalier Universitaire de Martinique), Susanne Clinch(Université de Bordeaux), Mark S. Freedman(University of Ottawa), Ralph H. B. Benedict(Jacobs Institute), Timothy Vollmer(Barrow Neurological Institute), Karen Kadner(Université de Bordeaux), Jens Wuerfel(Roche (Switzerland)), Ludo Vanopdenbosch(Université de Bordeaux), Thomas Berger(Medical University of Vienna), Catarina Raposo(Université de Bordeaux), Inessa Kulyk(Université de Bordeaux), Trygve Holmøy(OsloMet – Oslo Metropolitan University), Francesco Patti(University of Catania), Rana Karabudak(Hacettepe University), Bruno Brochet(Université de Bordeaux), Thomas Kuenzel(Université de Bordeaux), Gian‐Andrea Thanei(Université de Bordeaux), Robert A Bermel(Cleveland Clinic), Amy Perrin Ross(Université de Bordeaux), Carlos Nos(Universitat Autònoma de Barcelona)
Cited by 15
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
|Neurology|2015|4.6k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k